Table 3. Pooled mean HCV prevalence and meta-analysis summary statistics by risk population in Djibouti, Somalia. Sudan and Yemen.
| Number of studies | Total sample size | Prevalence range (%)* | Effect size | Heterogeneity | ||||
|---|---|---|---|---|---|---|---|---|
| Mean prevalence (%) | Confidence interval (95%) | Q (p-value) | I2 (confidence interval) | Prediction interval (95%) | ||||
| Djibouti | ||||||||
| High-risk groups | 0 | 0 | - | - | - | - | - | - |
| Intermediate-risk groups | 0 | 0 | - | - | - | - | - | - |
| Special clinical populations | 0 | 0 | - | - | - | - | - | - |
| General population | 1 | 8,057 | 0.3 | - | 0.1–0.4 | - | - | - |
| Somalia | ||||||||
| High-risk groups | 0 | 0 | - | - | - | - | - | - |
| Intermediate-risk groups | 5 | 702 | 0.0–7.0 | 1.7 | 0.0–4.9 | 17.3 (0.002) | 77% (44%-90%) | 0.0–18.2 |
| Special clinical populations | 2 | 172 | 14.5–40.3 | - | - | - | - | - |
| General population | 9 | 14,081 | 0.0–6.5 | 0.9 | 0.3–1.9 | 24.0 (0.002) | 67% (32%-83%) | 0.0–4.3 |
| Sudan | ||||||||
| High-risk groups | 6 | 979 | 4.5–34.8 | 17.3 | 8.6–28.2 | 74.6 (<0.0001) | 93.3% (88%-96%) | 0.0–60.9 |
| Intermediate-risk groups | 23 | 6,450 | 0.0–5.4 | 0.6 | 0.4–0.8 | 103.5 (<0.0001) | 79% (69%-86%) | 0.0–4.3 |
| Special clinical populations | 2 | 131 | 6.3–11.0 | - | - | - | - | - |
| General population | 7 | 1,856 | 0.0–4.1 | 1.0 | 0.3–1.9 | 12.9 (0.045) | 53% (0%-80%) | 0.0–4.1 |
| Yemen | ||||||||
| High-risk groups | 3 | 300 | 40.0–62.7 | - | - | - | - | - |
| Intermediate-risk groups | 3 | 1,322 | 0.5–3.5 | - | - | - | - | - |
| Special clinical populations | 13 | 2,832 | 6.4–38.2 | 19.4 | 13.0–26.6 | 231.8 (<0.001) | 95% (93%-96%) | 0.9–51.8 |
| General population* | 24 | 48,343 | 0.0–8.5 | 1.9 | 1.4–2.6 | 345.3 (<0.001) | 93% (91%-96%) | 0.1–5.7 |
| All countries | ||||||||
| High-risk groups | 9 | 1,279 | 4.5–62.7 | 26.2 | 14.8–39.4 | 188.3 (<0.0001) | 95% (94%-97%) | 0.0–76.1 |
| Intermediate-risk groups | 31 | 8,474 | 0.0–7.0 | 0.7 | 0.3–1.3 | 139.5 (<0.001) | 79% (71%-85%) | 0.0–4.7 |
| Special clinical populations | 17 | 3,135 | 6.4–38.2 | 19.6 | 13.9–26.0 | 253.0 (<0.001) | 94% (92%-96%) | 1.4–50.2 |
| General population* | 41 | 72,337 | 0.0–8.5 | 1.5 | 1.0–2.2 | 1147.9 (<0.001) | 96% (96%-97%) | 0.0–7.0 |
*In the general population of Yemen, one study was not included in the meta-analysis as it reported HCV prevalence in a migrant non-Yemeni population.